Suppr超能文献

严重急性呼吸综合征冠状病毒2的起源与进化

Origin and evolution of SARS-CoV-2.

作者信息

Pagani Isabel, Ghezzi Silvia, Alberti Simone, Poli Guido, Vicenzi Elisa

机构信息

Viral Pathogenesis and Biosafety Unit, Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Via Olgettina, 58, Milan, Italy.

Human Immuno-Virology (H.I.V.) Unit, Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Via Olgettina, 58, Milan, Italy.

出版信息

Eur Phys J Plus. 2023;138(2):157. doi: 10.1140/epjp/s13360-023-03719-6. Epub 2023 Feb 16.

Abstract

SARS-CoV-2 is a novel coronavirus that emerged in China at the end of 2019 causing the severe disease known as coronavirus disease 2019 (COVID-19). SARS-CoV-2, as to the previously highly pathogenic human coronaviruses named SARS-CoV, the etiological agent of severe acute respiratory syndrome (SARS), has a zoonotic origin, although SARS-CoV-2 precise chain of animal-to-human transmission remains undefined. Unlike the 2002-2003 pandemic caused by SARS-CoV whose extinction from the human population was achieved in eight months, SARS-CoV-2 has been spreading globally in an immunologically naïve population in an unprecedented manner. The efficient infection and replication of SARS-CoV-2 has resulted in the emergence of viral variants that have become predominant posing concerns about their containment as they are more infectious with variable pathogenicity in respect to the original virus. Although vaccine availability is limiting severe disease and death caused by SARS-CoV-2 infection, its extinction is far to be close and predictable. In this regard, the emersion of the Omicron viral variant in November 2021 was characterized by humoral immune escape and it has reinforced the importance of the global monitoring of SARS-CoV-2 evolution. Given the importance of the SARS-CoV-2 zoonotic origin, it will also be crucial to monitor the animal-human interface to be better prepared to cope with future infections of pandemic potential.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种新型冠状病毒,于2019年底在中国出现,引发了被称为2019冠状病毒病(COVID-19)的严重疾病。与之前具有高致病性的人类冠状病毒严重急性呼吸综合征冠状病毒(SARS-CoV,即严重急性呼吸综合征的病原体)一样,SARS-CoV-2也源自动物,但SARS-CoV-2的确切人畜传播链仍不明确。与2002 - 2003年由SARS-CoV引发的疫情在八个月内就从人类中消失不同,SARS-CoV-2以前所未有的方式在全球免疫原初人群中传播。SARS-CoV-2的有效感染和复制导致了病毒变体的出现,这些变体已成为主要毒株,由于它们比原始病毒更具传染性且致病性各异,因此对其控制构成了担忧。尽管疫苗的可及性限制了SARS-CoV-2感染导致的严重疾病和死亡,但要使其消失还远非近在咫尺且可预测。在这方面,2021年11月出现的奥密克戎病毒变体具有体液免疫逃逸的特征,这凸显了全球监测SARS-CoV-2进化的重要性。鉴于SARS-CoV-2人畜共患病起源的重要性,监测动物与人类的接触界面对于更好地应对未来具有大流行潜力的感染也至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22f9/9933829/1c507ea7010b/13360_2023_3719_Fig1_HTML.jpg

相似文献

1
Origin and evolution of SARS-CoV-2.
Eur Phys J Plus. 2023;138(2):157. doi: 10.1140/epjp/s13360-023-03719-6. Epub 2023 Feb 16.
2
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
3
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
4
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
9
Managing the COVID-19 Pandemic: Research Strategies Based on the Evolutionary and Molecular Characteristics of Coronaviruses.
SN Compr Clin Med. 2020;2(10):1767-1776. doi: 10.1007/s42399-020-00457-z. Epub 2020 Aug 25.
10
Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes.
Med Rev (2021). 2022 Mar 1;2(1):3-22. doi: 10.1515/mr-2021-0035. eCollection 2022 Feb 1.

引用本文的文献

2
Spatial and socioeconomic patterns of COVID-19 in transition zones between municipalities in eastern Amazonia.
Front Public Health. 2025 Mar 13;13:1526642. doi: 10.3389/fpubh.2025.1526642. eCollection 2025.
4
Complement is primarily activated in the lung in a mouse model of severe COVID-19.
iScience. 2025 Feb 1;28(3):111930. doi: 10.1016/j.isci.2025.111930. eCollection 2025 Mar 21.
6
Distinct Responses of Cystic Fibrosis Epithelial Cells to SARS-CoV-2 and Influenza A Virus.
Am J Respir Cell Mol Biol. 2025 Mar;72(3):308-319. doi: 10.1165/rcmb.2024-0213OC.
7
Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.
Front Pharmacol. 2024 Jul 31;15:1381830. doi: 10.3389/fphar.2024.1381830. eCollection 2024.

本文引用的文献

1
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
3
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.
Nature. 2022 Mar;603(7902):687-692. doi: 10.1038/s41586-022-04441-6. Epub 2022 Jan 21.
4
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.
Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7.
5
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.
6
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
7
How bad is Omicron? What scientists know so far.
Nature. 2021 Dec;600(7888):197-199. doi: 10.1038/d41586-021-03614-z.
9
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.
Nature. 2021 Oct;598(7880):342-347. doi: 10.1038/s41586-021-03925-1. Epub 2021 Aug 31.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验